Posts Tagged Erlotinib
Exelixis, Inc. reported interim data from an ongoing Phase 1b/2 study of XL184 in patients with non-small cell lung cancer (NSCLC). Dr. Heather Wakelee from Stanford University School of Medicine in Stanford, CA will present the data in a poster discussion session on Sunday, June 6 at the 2010 [...]
Tags:
1b/2,
ASCO,
Cancer,
Data,
Encouraging,
Erlotinib,
Exelixis,
Interim,
Lung,
NonSmall,
Ongoing,
patients,
Phase,
Presented,
Reports,
Study,
Without,
XL184 Posted in
Cancer on | There are currently
No Comments
Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, [...]
Tags:
Cancer,
Data,
Erlotinib,
Identifies,
Likely,
Lung,
patients,
Phase,
Respond,
Trial,
VeriStrat Posted in
Cancer on | There are currently
No Comments
Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.
Source: General Cancer News Articles Provided by Cancer Compass